{"database": "openregs", "table": "documents", "is_view": false, "human_description_en": "where agency_id = \"FDA\" and posted_year = 2017 sorted by posted_date descending", "rows": [["FDA-2017-V-7020-0002", "FDA", "FDA-2017-V-7020", "Acknowledgment Letter from FDA DDM to W6 Restaurant Group LTD", "Other", "Acknowledgement Letter/Receipt", "2017-12-29T05:00:00Z", 2017, 12, "2017-12-29T05:00:00Z", null, "2017-12-29T16:38:57Z", null, 0, 0, "0900006482d83ab8"], ["FDA-2017-H-6960-0001", "FDA", "FDA-2017-H-6960", "Complaint", "Other", "Complaint", "2017-12-29T05:00:00Z", 2017, 12, "2017-12-29T05:00:00Z", null, "2017-12-29T18:59:43Z", null, 0, 0, "0900006482d84c25"], ["FDA-1994-P-0028-0047", "FDA", "FDA-1994-P-0028", "Tab G: Letter from Geneva Pharmaceuticals to FDA CDER re: Petition for Stay of Action from Geneva Pharmaceuticals, Inc. (McKenna & Cuneo)", "Supporting & Related Material", "Background Material", "2017-12-29T05:00:00Z", 2017, 12, null, null, "2017-12-29T16:45:07Z", null, 0, 0, "09000064804fd363"], ["FDA-2017-P-7032-0003", "FDA", "FDA-2017-P-7032", "Exhibit 1 Electronic Orange Book re Citizen Petition from Jubilant Generics Limited", "Supporting & Related Material", "Background Material", "2017-12-29T05:00:00Z", 2017, 12, null, null, "2018-01-02T16:48:54Z", null, 0, 0, "0900006482d84ab7"], ["FDA-2017-P-7034-0003", "FDA", "FDA-2017-P-7034", "Exhibit 1 Orange Book Listing re Citizen Petition from Jubilant Generics Limited", "Supporting & Related Material", "Background Material", "2017-12-29T05:00:00Z", 2017, 12, null, null, "2018-01-02T16:53:20Z", null, 0, 0, "0900006482d84d72"], ["FDA-2017-P-7034-0005", "FDA", "FDA-2017-P-7034", "Exhibit 3 Proposed Product Draft Label re Citizen Petition from Jubilant Generics Limited", "Supporting & Related Material", "Background Material", "2017-12-29T05:00:00Z", 2017, 12, null, null, "2018-01-02T16:53:46Z", null, 0, 0, "0900006482d84d74"], ["FDA-2017-P-7032-0005", "FDA", "FDA-2017-P-7032", "Exhibit 3 Draft Labeling for proposed product re Citizen Petition from Jubilant Generics Limited", "Supporting & Related Material", "Background Material", "2017-12-29T05:00:00Z", 2017, 12, null, null, "2018-01-02T16:49:28Z", null, 0, 0, "0900006482d84aba"], ["FDA-2017-H-6973-0001", "FDA", "FDA-2017-H-6973", "Complaint", "Other", "Complaint", "2017-12-29T05:00:00Z", 2017, 12, "2017-12-29T05:00:00Z", null, "2017-12-29T19:30:07Z", null, 0, 0, "0900006482d84ca5"], ["FDA-2017-V-7020-0001", "FDA", "FDA-2017-V-7020", "Variance Application from W6 Restaurant Group LTD", "Other", "Application for Variance (VAR)", "2017-12-29T05:00:00Z", 2017, 12, "2017-12-29T05:00:00Z", null, "2017-12-29T16:38:51Z", null, 0, 0, "0900006482d83ab6"], ["FDA-2017-P-7031-0002", "FDA", "FDA-2017-P-7031", "Acknowledgment Letter from FDA DDM to JRRapoza Associates, Inc", "Other", "Acknowledgement Letter/Receipt", "2017-12-29T05:00:00Z", 2017, 12, "2017-12-29T05:00:00Z", null, "2017-12-29T17:34:05Z", null, 0, 0, "0900006482d8388f"], ["FDA-2017-P-7032-0001", "FDA", "FDA-2017-P-7032", "Citizen Petition from Jubilant Generics Limited", "Other", "Citizen Petition", "2017-12-29T05:00:00Z", 2017, 12, "2017-12-29T05:00:00Z", "2018-06-28T03:59:59Z", "2018-01-02T16:48:06Z", null, 0, 0, "0900006482d843bf"], ["FDA-2017-V-7023-0001", "FDA", "FDA-2017-V-7023", "Variance Application from Platinum AVL", "Other", "Application for Variance (VAR)", "2017-12-29T05:00:00Z", 2017, 12, "2017-12-29T05:00:00Z", null, "2017-12-29T16:37:20Z", null, 0, 0, "0900006482d83c59"], ["FDA-2017-P-7033-0004", "FDA", "FDA-2017-P-7033", "Exhibit 2 RLD Label re Citizen Petition from Jubliant Generics Limited", "Supporting & Related Material", "Background Material", "2017-12-29T05:00:00Z", 2017, 12, null, null, "2018-01-02T16:51:33Z", null, 0, 0, "0900006482d84da8"], ["FDA-2017-P-7033-0006", "FDA", "FDA-2017-P-7033", "Exhibit 4 Oxetol Dosage & Drug Information re Citizen Petition from Jubliant Generics Limited", "Supporting & Related Material", "Background Material", "2017-12-29T05:00:00Z", 2017, 12, null, null, "2018-01-02T16:51:56Z", null, 0, 0, "0900006482d84daa"], ["FDA-1977-N-0025-0008", "FDA", "FDA-1977-N-0025", "Literature References re: Supplement from Wyeth Consumer Healthcare", "Supporting & Related Material", "Background Material", "2017-12-29T05:00:00Z", 2017, 12, "2017-12-29T05:00:00Z", null, "2019-02-04T14:04:52Z", null, 0, 0, "09000064805da2fa"], ["FDA-1977-N-0025-0007", "FDA", "FDA-1977-N-0025", "Supplement from Wyeth Consumer Healthcare", "Other", "Supplement (SUP)", "2017-12-29T05:00:00Z", 2017, 12, "2017-12-29T05:00:00Z", null, "2019-02-01T15:40:00Z", null, 0, 0, "09000064805da2f9"], ["FDA-2017-H-6986-0001", "FDA", "FDA-2017-H-6986", "Complaint", "Other", "Complaint", "2017-12-29T05:00:00Z", 2017, 12, "2017-12-29T05:00:00Z", null, "2017-12-29T20:05:43Z", null, 0, 0, "0900006482d85162"], ["FDA-2017-V-7021-0002", "FDA", "FDA-2017-V-7021", "Acknowledgment Letter from FDA DDM to Trio Nightclub", "Other", "Acknowledgement Letter/Receipt", "2017-12-29T05:00:00Z", 2017, 12, "2017-12-29T05:00:00Z", null, "2017-12-29T16:41:48Z", null, 0, 0, "0900006482d83abe"], ["FDA-2014-P-0646-0011", "FDA", "FDA-2014-P-0646", "Letter from Kamat Pharmatech to FDA DDM", "Other", "Letter(s)", "2017-12-29T05:00:00Z", 2017, 12, "2017-12-29T05:00:00Z", null, "2017-12-29T16:42:48Z", null, 0, 0, "0900006482d8388b"], ["FDA-2017-P-7032-0002", "FDA", "FDA-2017-P-7032", "Acknowledgment Letter from FDA DDM to Jubilant Generics Limited", "Other", "Acknowledgement Letter/Receipt", "2017-12-29T05:00:00Z", 2017, 12, "2017-12-29T05:00:00Z", null, "2018-01-02T16:48:30Z", null, 0, 0, "0900006482d843c1"], ["FDA-2017-H-6948-0001", "FDA", "FDA-2017-H-6948", "Complaint", "Other", "Complaint", "2017-12-29T05:00:00Z", 2017, 12, "2017-12-29T05:00:00Z", null, "2017-12-29T18:48:22Z", null, 0, 0, "0900006482d84e08"], ["FDA-1994-P-0028-0046", "FDA", "FDA-1994-P-0028", "Tab G: Letter from Geneva Pharmaceuticals to FDA CDER re Correction from Geneva Pharmaceuticals, Inc. (Mckenna & Cuneo)", "Supporting & Related Material", "Background Material", "2017-12-29T05:00:00Z", 2017, 12, null, null, "2017-12-29T16:44:36Z", null, 0, 0, "09000064804fd353"], ["FDA-2017-P-7033-0001", "FDA", "FDA-2017-P-7033", "Citizen Petition from Jubliant Generics Limited", "Other", "Citizen Petition", "2017-12-29T05:00:00Z", 2017, 12, "2017-12-29T05:00:00Z", "2018-06-28T03:59:59Z", "2018-01-02T16:50:17Z", null, 0, 0, "0900006482d84d79"], ["FDA-2017-H-6958-0001", "FDA", "FDA-2017-H-6958", "Complaint", "Other", "Complaint", "2017-12-29T05:00:00Z", 2017, 12, "2017-12-29T05:00:00Z", null, "2017-12-29T18:54:54Z", null, 0, 0, "0900006482d84e3e"], ["FDA-2017-H-6952-0001", "FDA", "FDA-2017-H-6952", "Complaint", "Other", "Complaint", "2017-12-29T05:00:00Z", 2017, 12, "2017-12-29T05:00:00Z", null, "2017-12-29T18:47:45Z", null, 0, 0, "0900006482d84e02"], ["FDA-2017-D-6530-0002", "FDA", "FDA-2017-D-6530", "Formal Meetings Between the FDA and Sponsors or Applicants of PDUFA Products Guidance for Industry DRAFT GUIDANCE", "Other", "Guidance", "2017-12-29T05:00:00Z", 2017, 12, "2017-12-29T05:00:00Z", "2018-03-30T03:59:59Z", "2024-11-07T01:15:37Z", null, 1, 0, "0900006482d7eb25"], ["FDA-2017-D-6564-0002", "FDA", "FDA-2017-D-6564", "Best Practices for Communication Between IND Sponsors and FDA\nDuring Drug Development Guidance for Industry and Review Staff", "Other", "Guidance", "2017-12-29T05:00:00Z", 2017, 12, "2017-12-29T05:00:00Z", null, "2024-11-07T01:15:37Z", null, 1, 0, "0900006482d7eb23"], ["FDA-2017-P-7031-0003", "FDA", "FDA-2017-P-7031", "Attachment 1 Orange Book Listing re Citizen Petition from JRRapoza Associates, Inc", "Supporting & Related Material", "Background Material", "2017-12-29T05:00:00Z", 2017, 12, null, null, "2017-12-29T17:34:25Z", null, 0, 0, "0900006482d83891"], ["FDA-2017-P-7033-0002", "FDA", "FDA-2017-P-7033", "Acknowledgment Letter from FDA DDM to Jubilant Generics Limited", "Other", "Acknowledgement Letter/Receipt", "2017-12-29T05:00:00Z", 2017, 12, "2017-12-29T05:00:00Z", null, "2018-01-02T16:50:45Z", null, 0, 0, "0900006482d84da4"], ["FDA-2017-P-7034-0001", "FDA", "FDA-2017-P-7034", "Citizen Petition from Jubilant Generics Limited", "Other", "Citizen Petition", "2017-12-29T05:00:00Z", 2017, 12, "2017-12-29T05:00:00Z", "2018-06-28T03:59:59Z", "2018-01-02T16:52:40Z", null, 0, 0, "0900006482d84d2a"], ["FDA-2017-P-7031-0001", "FDA", "FDA-2017-P-7031", "Citizen Petition from JRRapoza Associates, Inc", "Other", "Citizen Petition", "2017-12-29T05:00:00Z", 2017, 12, "2017-12-29T05:00:00Z", "2018-06-28T03:59:59Z", "2017-12-29T17:33:49Z", null, 0, 0, "0900006482d8388d"], ["FDA-2017-P-7032-0004", "FDA", "FDA-2017-P-7032", "Exhibit 2 RLD Labeling re Citizen Petition from Jubilant Generics Limited", "Supporting & Related Material", "Background Material", "2017-12-29T05:00:00Z", 2017, 12, null, null, "2018-01-02T16:49:10Z", null, 0, 0, "0900006482d84ab8"], ["FDA-2017-P-7034-0006", "FDA", "FDA-2017-P-7034", "Exhibit 4 Valtrex Tablets 250 mg re Citizen Petition from Jubilant Generics Limited", "Supporting & Related Material", "Background Material", "2017-12-29T05:00:00Z", 2017, 12, null, null, "2018-01-02T16:53:57Z", null, 0, 0, "0900006482d84d75"], ["FDA-2017-P-7031-0004", "FDA", "FDA-2017-P-7031", "Attachment 2 Approved Drug Labeling RLD re Citizen Petition from JRRapoza Associates, Inc", "Supporting & Related Material", "Background Material", "2017-12-29T05:00:00Z", 2017, 12, null, null, "2017-12-29T17:34:41Z", null, 0, 0, "0900006482d84574"], ["FDA-2017-D-6564-0001", "FDA", "FDA-2017-D-6564", "Best Practices for Communication Between Investigational New Drug\nApplication Sponsors and the Food and Drug Administration; Guidance for Industry and Review Staff; Availability", "Notice", "Notice of Availability", "2017-12-29T05:00:00Z", 2017, 12, "2017-12-29T05:00:00Z", null, "2017-12-29T14:28:34Z", "2017-28139", 0, 0, "0900006482d832c0"], ["FDA-2017-D-6530-0001", "FDA", "FDA-2017-D-6530", "Formal Meetings Between the Food and Drug Administration and Sponsors or Applicants of Prescription Drug User Fee Act Products; Draft Guidance for Industry; Availability", "Notice", "Notice of Availability", "2017-12-29T05:00:00Z", 2017, 12, "2017-12-29T05:00:00Z", "2018-03-30T03:59:59Z", "2018-03-28T01:02:41Z", "2017-28140", 0, 0, "0900006482d832bd"], ["FDA-2016-N-0832-0057", "FDA", "FDA-2016-N-0832", "Letter from Phibro Animal Health Corporation", "Other", "Letter(s)", "2017-12-29T05:00:00Z", 2017, 12, "2017-12-29T05:00:00Z", null, "2017-12-29T15:57:53Z", null, 0, 0, "0900006482d83a18"], ["FDA-2017-V-7023-0002", "FDA", "FDA-2017-V-7023", "Acknowledgement Letter from FDA DDM to Platinum AVL", "Other", "Acknowledgement Letter/Receipt", "2017-12-29T05:00:00Z", 2017, 12, "2017-12-29T05:00:00Z", null, "2017-12-29T16:37:25Z", null, 0, 0, "0900006482d83c5c"], ["FDA-2017-P-7033-0003", "FDA", "FDA-2017-P-7033", "Exhibit 1 Orange Book Listing re Citizen Petition from Jubliant Generics Limited", "Supporting & Related Material", "Background Material", "2017-12-29T05:00:00Z", 2017, 12, null, null, "2018-01-02T16:51:21Z", null, 0, 0, "0900006482d84da7"], ["FDA-2017-P-7033-0005", "FDA", "FDA-2017-P-7033", "Exhibit 3 Proposed Product Draft Label re Citizen Petition from Jubliant Generics Limited", "Supporting & Related Material", "Background Material", "2017-12-29T05:00:00Z", 2017, 12, null, null, "2018-01-02T16:51:45Z", null, 0, 0, "0900006482d84da9"], ["FDA-2017-V-7028-0002", "FDA", "FDA-2017-V-7028", "Acknowledgement Letter from FDA DDM to Richard Nguyen", "Other", "Acknowledgement Letter/Receipt", "2017-12-29T05:00:00Z", 2017, 12, "2017-12-29T05:00:00Z", null, "2017-12-29T18:19:48Z", null, 0, 0, "0900006482d84abf"], ["FDA-2017-H-6963-0001", "FDA", "FDA-2017-H-6963", "Complaint", "Other", "Complaint", "2017-12-29T05:00:00Z", 2017, 12, "2017-12-29T05:00:00Z", null, "2017-12-29T19:24:17Z", null, 0, 0, "0900006482d84efa"], ["FDA-2017-P-7034-0004", "FDA", "FDA-2017-P-7034", "Exhibit 2 RLD Label re Citizen Petition from Jubilant Generics Limited", "Supporting & Related Material", "Background Material", "2017-12-29T05:00:00Z", 2017, 12, null, null, "2018-01-02T16:53:34Z", null, 0, 0, "0900006482d84d73"], ["FDA-2017-P-7034-0002", "FDA", "FDA-2017-P-7034", "Acknowledgment Letter from FDA DDM to Jubilant Generics Limited", "Other", "Acknowledgement Letter/Receipt", "2017-12-29T05:00:00Z", 2017, 12, "2017-12-29T05:00:00Z", null, "2018-01-02T16:53:05Z", null, 0, 0, "0900006482d84d2c"], ["FDA-2017-H-6953-0001", "FDA", "FDA-2017-H-6953", "Complaint", "Other", "Complaint", "2017-12-29T05:00:00Z", 2017, 12, "2017-12-29T05:00:00Z", null, "2017-12-29T18:45:41Z", null, 0, 0, "0900006482d84e38"], ["FDA-2017-V-7021-0001", "FDA", "FDA-2017-V-7021", "Variance Application from Trio Nightclub", "Other", "Application for Variance (VAR)", "2017-12-29T05:00:00Z", 2017, 12, "2017-12-29T05:00:00Z", null, "2017-12-29T16:41:43Z", null, 0, 0, "0900006482d83abc"], ["FDA-2017-V-7028-0001", "FDA", "FDA-2017-V-7028", "Variance Application from RICHARD NGUYEN", "Other", "Application for Variance (VAR)", "2017-12-29T05:00:00Z", 2017, 12, "2017-12-29T05:00:00Z", null, "2017-12-29T18:19:42Z", null, 0, 0, "0900006482d837cd"], ["FDA-2017-H-6972-0001", "FDA", "FDA-2017-H-6972", "Complaint", "Other", "Complaint", "2017-12-29T05:00:00Z", 2017, 12, "2017-12-29T05:00:00Z", null, "2017-12-29T19:11:59Z", null, 0, 0, "0900006482d84ef4"], ["FDA-1977-N-0025-0009", "FDA", "FDA-1977-N-0025", "Mail Slip re: Supplement from Wyeth Consumer Healthcare", "Supporting & Related Material", "Transmittals", "2017-12-29T05:00:00Z", 2017, 12, "2017-12-29T05:00:00Z", null, "2019-02-04T14:03:07Z", null, 0, 0, "09000064805da2fb"], ["FDA-1980-N-0038-0121", "FDA", "FDA-1980-N-0038", "Evaluation of a Topical Steroid Antibiotic Combination (Halcinonide-Neomycin-Amphotericin) in the Treatment of Cutaneous Candidiasis and Inflammatory Dermatoses re: Supplement from National Pharmaceutical Alliance", "Supporting & Related Material", "Background Material", "2017-12-28T05:00:00Z", 2017, 12, null, null, "2017-12-28T17:56:50Z", null, 0, 0, "09000064805b9631"], ["FDA-1980-N-0038-0138", "FDA", "FDA-1980-N-0038", "Certain Topical Anti-Infective Drug Products; Vioform-Hydrocortisone (Iodochlorhydroxyquin and Hydrocortisone) Request of CIBA-GEIGY Corporation for Hearing Vol I re: Supplement from CIBA-GEIGY (Wald, Harkrader & Ross) (Vol 1 of 3)", "Other", "Supplement (SUP)", "2017-12-28T05:00:00Z", 2017, 12, null, null, "2017-12-28T18:11:59Z", null, 0, 0, "09000064805b963e"], ["FDA-2017-P-4039-0003", "FDA", "FDA-2017-P-4039", "Interim Response Letter from FDA CDER to Center for Lawful Access and Abuse Deterrence", "Other", "Letter(s)", "2017-12-28T05:00:00Z", 2017, 12, "2017-12-28T05:00:00Z", null, "2017-12-28T21:28:04Z", null, 0, 0, "0900006482d7f298"], ["FDA-2005-D-0140-0012", "FDA", "FDA-2005-D-0140", "Reference 1 FDA Memorandum to All Registered Blood Establishments: \u201cRevised Recommendations for the Prevention of Human Immunodeficiency Virus (HIV-1) Transmission by Blood and Blood Products,\u201d", "Supporting & Related Material", "Background Material", "2017-12-28T05:00:00Z", 2017, 12, null, null, "2017-12-28T20:40:42Z", null, 0, 0, "0900006482d7ee3f"], ["FDA-2005-D-0140-0015", "FDA", "FDA-2005-D-0140", "Reference 4 Busch MP. Closing the windows on viral transmission by blood transfusion. In Stramer SL ed. Blood Safety in the New Millenium. Bethesda, MD: American Association of Blood Banks, 2001: Chapter 2, p.36.", "Supporting & Related Material", "Background Material", "2017-12-28T05:00:00Z", 2017, 12, null, null, "2017-12-28T20:40:28Z", null, 0, 0, "0900006482d7ee42"], ["FDA-1980-N-0038-0150", "FDA", "FDA-1980-N-0038", "Supplement from Burroughs Wellcome Co. (Vol. 3 of 5)", "Supporting & Related Material", "Background Material", "2017-12-28T05:00:00Z", 2017, 12, null, null, "2017-12-28T19:19:03Z", null, 0, 0, "0900006482cd5c29"], ["FDA-2015-V-0429-0003", "FDA", "FDA-2015-V-0429", "Approval Letter from FDA CDRH to Power Technology, Inc.", "Other", "Approval for Variance (VRA)", "2017-12-28T05:00:00Z", 2017, 12, "2017-12-28T05:00:00Z", null, "2017-12-28T15:21:49Z", null, 0, 0, "0900006482d7b398"], ["FDA-2017-H-6956-0001", "FDA", "FDA-2017-H-6956", "Complaint", "Other", "Complaint", "2017-12-28T05:00:00Z", 2017, 12, "2017-12-28T05:00:00Z", null, "2017-12-28T15:55:12Z", null, 0, 0, "0900006482d7b912"], ["FDA-2017-H-6957-0001", "FDA", "FDA-2017-H-6957", "Complaint", "Other", "Complaint", "2017-12-28T05:00:00Z", 2017, 12, "2017-12-28T05:00:00Z", null, "2017-12-28T18:31:50Z", null, 0, 0, "0900006482d7c0f5"], ["FDA-2017-H-6954-0001", "FDA", "FDA-2017-H-6954", "Complaint", "Other", "Complaint", "2017-12-28T05:00:00Z", 2017, 12, "2017-12-28T05:00:00Z", null, "2017-12-28T15:25:41Z", null, 0, 0, "0900006482d7b39a"], ["FDA-2017-H-6962-0001", "FDA", "FDA-2017-H-6962", "Complaint", "Other", "Complaint", "2017-12-28T05:00:00Z", 2017, 12, "2017-12-28T05:00:00Z", null, "2017-12-28T19:21:49Z", null, 0, 0, "0900006482d7db54"], ["FDA-2001-N-0437-0003", "FDA", "FDA-2001-N-0437", "Supporting Statement - The Current Good Manufacturing Practice for Medicated Feeds", "Supporting & Related Material", "Background Material", "2017-12-28T05:00:00Z", 2017, 12, null, null, "2024-11-25T16:34:48Z", null, 0, 0, "09000064804e8893"], ["FDA-2005-D-0140-0010", "FDA", "FDA-2005-D-0140", "Nucleic Acid Testing (NAT) for Human Immunodeficiency Virus Type 1 (HIV-1) and Hepatitis C Virus (HCV): Testing, Product Disposition, and Donor Deferral and Reentry:  Guidance for Industry", "Other", "Guidance", "2017-12-28T05:00:00Z", 2017, 12, "2017-12-28T05:00:00Z", null, "2024-11-07T01:15:24Z", null, 1, 0, "0900006482d7ee3c"], ["FDA-2005-D-0140-0016", "FDA", "FDA-2005-D-0140", "Reference 5 Glynn SA, Kleinman SH, Wright DJ, Busch MP. International application of the incidence rate/window period model. Transfusion 42:966-972 (2002).", "Supporting & Related Material", "Background Material", "2017-12-28T05:00:00Z", 2017, 12, null, null, "2017-12-28T20:40:23Z", null, 0, 0, "0900006482d7ee43"], ["FDA-2017-H-6965-0001", "FDA", "FDA-2017-H-6965", "Complaint", "Other", "Complaint", "2017-12-28T05:00:00Z", 2017, 12, "2017-12-28T05:00:00Z", null, "2017-12-28T19:25:13Z", null, 0, 0, "0900006482d7e13f"], ["FDA-2005-D-0140-0022", "FDA", "FDA-2005-D-0140", "Reference 11 Alter HJ. To C or not to C: These are the questions. Blood 85:1681-1695 (1995).", "Supporting & Related Material", "Background Material", "2017-12-28T05:00:00Z", 2017, 12, null, null, "2017-12-28T20:39:54Z", null, 0, 0, "0900006482d7ee52"], ["FDA-2005-D-0140-0011", "FDA", "FDA-2005-D-0140", "001 - List of References - Nucleic Acid Testing (NAT) for Human Immunodeficiency Virus Type 1 (HIV-1) and Hepatitis C Virus (HCV): Testing, Product Disposition, and Donor Deferral and Reentry Guidance for Industry", "Supporting & Related Material", "Background Material", "2017-12-28T05:00:00Z", 2017, 12, null, null, "2017-12-28T20:40:50Z", null, 0, 0, "0900006482d7ee3e"], ["FDA-2005-D-0140-0021", "FDA", "FDA-2005-D-0140", "Reference 10 Blood Products Advisory Committee, 69th Meeting, June 14, 2001", "Supporting & Related Material", "Background Material", "2017-12-28T05:00:00Z", 2017, 12, null, null, "2017-12-28T20:39:59Z", null, 0, 0, "0900006482d7ee51"], ["FDA-1980-N-0038-0156", "FDA", "FDA-1980-N-0038", "Request for Hearing from Clay-Park Labs, Inc.", "Other", "Request for Hearing", "2017-12-28T05:00:00Z", 2017, 12, null, null, "2017-12-28T19:23:17Z", null, 0, 0, "09000064805b964a"], ["FDA-1980-N-0038-0141", "FDA", "FDA-1980-N-0038", "Letter from Miles Laboratories, Inc. to FDA/DDM", "Other", "Letter(s)", "2017-12-28T05:00:00Z", 2017, 12, null, null, "2017-12-28T18:13:51Z", null, 0, 0, "09000064805b963f"], ["FDA-1980-N-0038-0122", "FDA", "FDA-1980-N-0038", "Clinical Evaluation of a New Halcinonide-Antifungal Combination re: Supplement from National Pharmaceutical Alliance", "Supporting & Related Material", "Background Material", "2017-12-28T05:00:00Z", 2017, 12, null, null, "2017-12-28T17:57:25Z", null, 0, 0, "09000064805b9632"], ["FDA-1980-N-0038-0120", "FDA", "FDA-1980-N-0038", "Combined Steroid-Antiinfective Topical Therapy in Common Dermatoses A Double- Blind, Multi-Center Study of Iodochlorhydroxyquin-Hydrocortisone in 277 Patients re: Supplement from National Pharmaceutical Alliance", "Supporting & Related Material", "Background Material", "2017-12-28T05:00:00Z", 2017, 12, null, null, "2017-12-28T17:55:20Z", null, 0, 0, "09000064805b9630"], ["FDA-2005-D-0140-0019", "FDA", "FDA-2005-D-0140", "Reference 8 Federal Register, December 14, 1999 (64 FR 71147), Guidance for Industry: In the Manufacture and Clinical Evaluation of In Vitro Tests to Detect Nucleic Acid Sequences of Human Immunodeficiency Viruses Types 1 and 2, December 1999.", "Supporting & Related Material", "Background Material", "2017-12-28T05:00:00Z", 2017, 12, null, null, "2017-12-28T20:40:08Z", null, 0, 0, "0900006482d7ee4f"], ["FDA-2005-D-0140-0020", "FDA", "FDA-2005-D-0140", "Reference 9 Federal Register, August 24, 2007 (72 FR 48765), Current Good Manufacturing Practice for Blood and Blood Components; Notification of Consignees and Transfusion Recipients Receiving Blood and Blood Components at Increased Risk of Transmitting Hepatitis C Virus Infection (\u201cLookback\u201d); Final Rule.", "Supporting & Related Material", "Background Material", "2017-12-28T05:00:00Z", 2017, 12, null, null, "2017-12-28T20:40:03Z", null, 0, 0, "0900006482d7ee50"], ["FDA-2001-N-0437-0004", "FDA", "FDA-2001-N-0437", "Agency Information Collection Activities; Announcement of OMB Approval; Current Good Manufacturing Practice Regulations for Medicated Feeds", "Notice", "Notice of Approval", "2017-12-28T05:00:00Z", 2017, 12, null, null, "2024-11-25T16:30:52Z", "01\u201325763", 0, 0, "09000064804e8894"], ["FDA-1980-N-0038-0153", "FDA", "FDA-1980-N-0038", "Answer Letter from Arthur Hull Hayes, Jr. to American Academy of Dermatology, Inc.", "Other", "Answer", "2017-12-28T05:00:00Z", 2017, 12, null, null, "2017-12-28T19:21:20Z", null, 0, 0, "09000064805b9647"], ["FDA-1980-N-0038-0155", "FDA", "FDA-1980-N-0038", "Letter from Linda M. Quinones to American Academy of Dermatology, Inc.", "Other", "Letter(s)", "2017-12-28T05:00:00Z", 2017, 12, null, null, "2017-12-28T19:22:12Z", null, 0, 0, "09000064805b9649"], ["FDA-1980-N-0038-0128", "FDA", "FDA-1980-N-0038", "Iodochlorhydroxyquin-Hydrocortisone Treatment of Fungal Infections re: Supplement from National Pharmaceutical Alliance", "Supporting & Related Material", "Background Material", "2017-12-28T05:00:00Z", 2017, 12, null, null, "2017-12-28T18:00:02Z", null, 0, 0, "09000064805b9638"], ["FDA-1980-N-0038-0148", "FDA", "FDA-1980-N-0038", "Supplement from Burroughs Wellcome Co. (Vol. 1 of 5)", "Other", "Supplement (SUP)", "2017-12-28T05:00:00Z", 2017, 12, null, null, "2020-01-31T06:55:40Z", null, 0, 0, "09000064805b9646"], ["FDA-1980-N-0038-0152", "FDA", "FDA-1980-N-0038", "Supplement from Burroughs Wellcome Co. (Vol. 5 of 5)", "Supporting & Related Material", "Background Material", "2017-12-28T05:00:00Z", 2017, 12, null, null, "2017-12-28T19:19:25Z", null, 0, 0, "0900006482cd4ff8"], ["FDA-1980-N-0038-0151", "FDA", "FDA-1980-N-0038", "Supplement from Burroughs Wellcome Co. (Vol. 4 of 5)", "Supporting & Related Material", "Background Material", "2017-12-28T05:00:00Z", 2017, 12, null, null, "2017-12-28T19:19:13Z", null, 0, 0, "0900006482cd5304"], ["FDA-2017-N-6778-0001", "FDA", "FDA-2017-N-6778", "Fostering Medical Innovation: Case for Quality Voluntary Medical Device\nManufacturing and Product Quality Pilot Program", "Notice", "Announcement", "2017-12-28T05:00:00Z", 2017, 12, "2017-12-28T05:00:00Z", null, "2017-12-28T14:57:25Z", "2017-28044", 0, 0, "0900006482d7a81e"], ["FDA-2005-D-0140-0018", "FDA", "FDA-2005-D-0140", "Reference 7 Fiebig EW, Wright DJ, Rawal BD, et. al. Dynamics of HIV-1 viremia and antibody seroconversion in plasma donors: Implications for diagnosis and staging of primary HIV-1 infection. AIDS 17:1871-1879 (2003).", "Supporting & Related Material", "Background Material", "2017-12-28T05:00:00Z", 2017, 12, null, null, "2017-12-28T20:40:13Z", null, 0, 0, "0900006482d7ee4e"], ["FDA-1980-N-0038-0133", "FDA", "FDA-1980-N-0038", "Supplement from Merck Sharp & Dohme Research Labs (Vol. 1 of 4)", "Other", "Supplement (SUP)", "2017-12-28T05:00:00Z", 2017, 12, null, null, "2017-12-28T18:05:18Z", null, 0, 0, "09000064805b963c"], ["FDA-1980-N-0038-0142", "FDA", "FDA-1980-N-0038", "Withdrawal Letter from Miles Laboratories, Inc.", "Other", "Withdrawal", "2017-12-28T05:00:00Z", 2017, 12, null, null, "2017-12-28T18:19:41Z", null, 0, 0, "09000064805b9640"], ["FDA-2017-H-6964-0001", "FDA", "FDA-2017-H-6964", "Complaint", "Other", "Complaint", "2017-12-28T05:00:00Z", 2017, 12, "2017-12-28T05:00:00Z", null, "2017-12-28T19:23:34Z", null, 0, 0, "0900006482d7db87"], ["FDA-2017-V-6985-0001", "FDA", "FDA-2017-V-6985", "Variance Application from Aka Booking Agency", "Other", "Application for Variance (VAR)", "2017-12-28T05:00:00Z", 2017, 12, "2017-12-28T05:00:00Z", null, "2017-12-28T15:15:52Z", null, 0, 0, "0900006482d73063"], ["FDA-2001-N-0437-0002", "FDA", "FDA-2001-N-0437", "Agency Information Collection Activities; Submission for OMB Review; Comment Request; Current Good Manufacturing Practice Regulations for Medicated Feeds", "Notice", "30 Day Proposed Information Collection", "2017-12-28T05:00:00Z", 2017, 12, "2001-06-15T04:00:00Z", "2001-07-17T03:59:59Z", "2024-11-25T16:25:48Z", "01-15081", 0, 0, "09000064804e8892"], ["FDA-2017-H-6966-0001", "FDA", "FDA-2017-H-6966", "Complaint", "Other", "Complaint", "2017-12-28T05:00:00Z", 2017, 12, "2017-12-28T05:00:00Z", null, "2017-12-28T19:32:32Z", null, 0, 0, "0900006482d7e147"], ["FDA-1980-N-0038-0147", "FDA", "FDA-1980-N-0038", "Supplement from Mayrand, Inc. Pharmaceuticals", "Other", "Supplement (SUP)", "2017-12-28T05:00:00Z", 2017, 12, null, null, "2020-01-31T06:55:39Z", null, 0, 0, "09000064805b9645"], ["FDA-1980-N-0038-0145", "FDA", "FDA-1980-N-0038", "Supplement from UAD Laboratories, Inc.", "Other", "Supplement (SUP)", "2017-12-28T05:00:00Z", 2017, 12, null, null, "2020-01-31T06:55:40Z", null, 0, 0, "09000064805b9643"], ["FDA-2005-D-0140-0014", "FDA", "FDA-2005-D-0140", "Reference 3 FDA Memorandum to All Registered Blood Establishments: \u201cRevised Recommendations for Testing Whole Blood, Blood Components, Source Plasma and Source Leukocytes for Antibody to Hepatitis C Virus Encoded Antigen (Anti-HCV),\u201d August 5, 1993.", "Supporting & Related Material", "Background Material", "2017-12-28T05:00:00Z", 2017, 12, null, null, "2017-12-28T20:40:33Z", null, 0, 0, "0900006482d7ee41"], ["FDA-1980-N-0038-0123", "FDA", "FDA-1980-N-0038", "Iodochlorhydroxyquin re: Supplement from National Pharmaceutical Alliance", "Supporting & Related Material", "Background Material", "2017-12-28T05:00:00Z", 2017, 12, null, null, "2017-12-28T17:58:13Z", null, 0, 0, "09000064805b9633"], ["FDA-1980-N-0038-0124", "FDA", "FDA-1980-N-0038", "Topical Vioform-Hydrocortisone in Varicose Ulcer re: Supplement from National Pharmaceutical Alliance", "Supporting & Related Material", "Background Material", "2017-12-28T05:00:00Z", 2017, 12, null, null, "2017-12-28T17:58:38Z", null, 0, 0, "09000064805b9634"], ["FDA-1980-N-0038-0119", "FDA", "FDA-1980-N-0038", "Supplement from National Pharmaceutical Alliance", "Other", "Supplement (SUP)", "2017-12-28T05:00:00Z", 2017, 12, null, null, "2017-12-28T18:02:14Z", null, 0, 0, "09000064805b962f"], ["FDA-1980-N-0038-0131", "FDA", "FDA-1980-N-0038", "Iodochlorohydroxyquinoline (Vioform) Hydrocortisone Cream and Lotion in Superficial Fungus Infections re: Supplement from National Pharmaceutical Alliance", "Supporting & Related Material", "Background Material", "2017-12-28T05:00:00Z", 2017, 12, null, null, "2017-12-28T18:02:02Z", null, 0, 0, "09000064805b963b"], ["FDA-1980-N-0038-0143", "FDA", "FDA-1980-N-0038", "Correction from the Lemmon Company", "Other", "Correction(s)", "2017-12-28T05:00:00Z", 2017, 12, null, null, "2018-01-02T20:45:08Z", null, 0, 0, "09000064805b9641"], ["FDA-1980-N-0038-0140", "FDA", "FDA-1980-N-0038", "Certain Topical Anti-Infective Drug Products; Vioform-Hydrocortisone (Iodochlorhydroxyquin and Hydrocortisone) Request of CIBA-GEIGY Corporation for Hearing Vol II re: Supplement from CIBA-GEIGY (Wald, Harkrader & Ross) (Vol. 3 of 3)", "Supporting & Related Material", "Background Material", "2017-12-28T05:00:00Z", 2017, 12, null, null, "2017-12-28T18:12:50Z", null, 0, 0, "0900006482ceabb3"], ["FDA-1980-N-0038-0125", "FDA", "FDA-1980-N-0038", "Management of Chronic Eczematoid Dermatitis of the Hands re: Supplement from National Pharmaceutical Alliance", "Supporting & Related Material", "Background Material", "2017-12-28T05:00:00Z", 2017, 12, null, null, "2017-12-28T17:59:02Z", null, 0, 0, "09000064805b9635"], ["FDA-1980-N-0038-0137", "FDA", "FDA-1980-N-0038", "The Proposal to Withdraw the New Drug Application for Terra-Cortril Topical Ointment (NDA 61-011, Section 446.567(a)) - Submission of Data for Terra-Cortril Topical Ointment re Supplement from Pfizer Inc.", "Other", "Supplement (SUP)", "2017-12-28T05:00:00Z", 2017, 12, null, null, "2017-12-28T18:11:19Z", null, 0, 0, "09000064805b963d"], ["FDA-1980-N-0038-0144", "FDA", "FDA-1980-N-0038", "Supplement from Marnel Pharmaceuticals, Inc.", "Other", "Supplement (SUP)", "2017-12-28T05:00:00Z", 2017, 12, null, null, "2020-01-31T07:27:06Z", null, 0, 0, "09000064805b9642"]], "truncated": false, "filtered_table_rows_count": 24468, "expanded_columns": [], "expandable_columns": [[{"column": "docket_id", "other_table": "dockets", "other_column": "id"}, "title"]], "columns": ["id", "agency_id", "docket_id", "title", "document_type", "subtype", "posted_date", "posted_year", "posted_month", "comment_start_date", "comment_end_date", "last_modified", "fr_doc_num", "open_for_comment", "withdrawn", "object_id"], "primary_keys": ["id"], "units": {}, "query": {"sql": "select id, agency_id, docket_id, title, document_type, subtype, posted_date, posted_year, posted_month, comment_start_date, comment_end_date, last_modified, fr_doc_num, open_for_comment, withdrawn, object_id from documents where \"agency_id\" = :p0 and \"posted_year\" = :p1 order by posted_date desc limit 101", "params": {"p0": "FDA", "p1": "2017"}}, "facet_results": {"agency_id": {"name": "agency_id", "type": "column", "hideable": false, "toggle_url": "/openregs/documents.json?agency_id=FDA&posted_year=2017", "results": [{"value": "FDA", "label": "FDA", "count": 24468, "toggle_url": "https://www.pawtectors.org/openregs/documents.json?posted_year=2017", "selected": true}], "truncated": false}, "document_type": {"name": "document_type", "type": "column", "hideable": false, "toggle_url": "/openregs/documents.json?agency_id=FDA&posted_year=2017", "results": [{"value": "Other", "label": "Other", "count": 18238, "toggle_url": "https://www.pawtectors.org/openregs/documents.json?agency_id=FDA&posted_year=2017&document_type=Other", "selected": false}, {"value": "Supporting & Related Material", "label": "Supporting & Related Material", "count": 5045, "toggle_url": "https://www.pawtectors.org/openregs/documents.json?agency_id=FDA&posted_year=2017&document_type=Supporting+%26+Related+Material", "selected": false}, {"value": "Notice", "label": "Notice", "count": 969, "toggle_url": "https://www.pawtectors.org/openregs/documents.json?agency_id=FDA&posted_year=2017&document_type=Notice", "selected": false}, {"value": "Rule", "label": "Rule", "count": 141, "toggle_url": "https://www.pawtectors.org/openregs/documents.json?agency_id=FDA&posted_year=2017&document_type=Rule", "selected": false}, {"value": "Proposed Rule", "label": "Proposed Rule", "count": 75, "toggle_url": "https://www.pawtectors.org/openregs/documents.json?agency_id=FDA&posted_year=2017&document_type=Proposed+Rule", "selected": false}], "truncated": false}, "posted_year": {"name": "posted_year", "type": "column", "hideable": false, "toggle_url": "/openregs/documents.json?agency_id=FDA&posted_year=2017", "results": [{"value": 2017, "label": 2017, "count": 24468, "toggle_url": "https://www.pawtectors.org/openregs/documents.json?agency_id=FDA", "selected": true}], "truncated": false}}, "suggested_facets": [{"name": "posted_month", "toggle_url": "https://www.pawtectors.org/openregs/documents.json?agency_id=FDA&posted_year=2017&_facet=posted_month"}, {"name": "open_for_comment", "toggle_url": "https://www.pawtectors.org/openregs/documents.json?agency_id=FDA&posted_year=2017&_facet=open_for_comment"}, {"name": "withdrawn", "toggle_url": "https://www.pawtectors.org/openregs/documents.json?agency_id=FDA&posted_year=2017&_facet=withdrawn"}, {"name": "posted_date", "type": "date", "toggle_url": "https://www.pawtectors.org/openregs/documents.json?agency_id=FDA&posted_year=2017&_facet_date=posted_date"}, {"name": "comment_start_date", "type": "date", "toggle_url": "https://www.pawtectors.org/openregs/documents.json?agency_id=FDA&posted_year=2017&_facet_date=comment_start_date"}, {"name": "comment_end_date", "type": "date", "toggle_url": "https://www.pawtectors.org/openregs/documents.json?agency_id=FDA&posted_year=2017&_facet_date=comment_end_date"}, {"name": "last_modified", "type": "date", "toggle_url": "https://www.pawtectors.org/openregs/documents.json?agency_id=FDA&posted_year=2017&_facet_date=last_modified"}], "next": "2017-12-28T05~3A00~3A00Z,FDA-1980-N-0038-0144", "next_url": "https://www.pawtectors.org/openregs/documents.json?agency_id=FDA&posted_year=2017&_next=2017-12-28T05~3A00~3A00Z%2CFDA-1980-N-0038-0144&_sort_desc=posted_date", "private": false, "allow_execute_sql": true, "query_ms": 1792.2606409993023, "source": "Federal Register API & Regulations.gov API", "source_url": "https://www.federalregister.gov/developers/api/v1", "license": "Public Domain (U.S. Government data)", "license_url": "https://www.regulations.gov/faq"}